3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
161
Neoplasm Metastasis
27
Neoplasms
25
Breast Neoplasms, Male
15
Brain Neoplasms
14
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Stomach Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Prostatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Glioblastoma
5
Carcinoma, Non-Small-Cell Lung
5
Esophageal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Salivary Gland Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Gliosarcoma
3
Glioma
3
Gallbladder Neoplasms
3
Ependymoma
3
Carcinoma, Squamous Cell
3
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Osteitis Deformans
2
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Bevacizumab
14
Cisplatin
12
Surveys and Questionnaires
11
Gemcitabine
9
Drug Therapy
9
Standard of Care
8
Nivolumab
7
Cetuximab
7
pembrolizumab
6
S 1 (combination)
6
Cyclophosphamide
6
atezolizumab
5
Specimen Handling
5
Endoscopic Mucosal Resection
5
Educational Status
5
Docetaxel
5
Blood Specimen Collection
5
fludarabine
4
aldesleukin
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
IFL protocol
4
Folfox protocol
4
Everolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Neoplasms
×
Lapatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled